Regardless, finding that a relative increase in SGLT1/SGLT2 inhibition reduces the risk of MI and stroke as well as hospitalizations and urgent visits for heart failure provides an opportunity to further improve quality of life for patients and reduce the healthcare burden associated with type 2 diabetes [49]. This evidence concerns the gene SLC5A1 and type 2 diabetes mellitus.